Predicted serum valproic acid concentrations in patients missing and replacing a dose of extended-release divalproex sodium

American Journal of Health-System Pharmacy

Volumn 61, Issue 21, 2004, Pages 2284-2289

  Reed, Ronald C ^a   Dutta, Sandeep ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Absorption; Anticonvulsants; Binding; Blood levels; Divalproex sodium; Dosage schedules; Drug distribution systems; Drugs; Drugs, body distribution; Excretion; Metabolism; Methodology; Pharmacokinetics; Sustained action medications; Toxicity; Valproic acid

Indexed keywords

VALPROATE SEMISODIUM; VALPROIC ACID;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BINDING SITE; COMPUTER SIMULATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG PROTEIN BINDING; ENZYME INDUCTION; EPILEPSY; HUMAN; PRIORITY JOURNAL; SUSTAINED RELEASE PREPARATION;

EID: 12544259806     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/61.21.2284     Document Type: Article

References (24)

1. Browne TR, Holmes GL. Epilepsy. N Engl J Med. 2001; 344:1145-51. [Erratum, N Engl J Med. 2001; 344:1956.]
2. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs. 2002; 16:695-714.
3. Mathew NT, Saper JR, Silberstein SD et al. Migraine prophylaxis with divalproex. Arch Neurol. 1995; 52:281-6.
4. Becker WJ. Evidence based migraine prophylactic drug therapy. Can J Neurol Sci. 1999; 26(suppl 3):S27-32.
5. Gugler R, von Unruh GE. Clinical pharmacokinetics of valproic acid. Clin Pharmacokinet. 1980; 5:67-83.
6. Zaccara G, Messori A, Moroni F. Clinical pharmacokinetics of valproic acid - 1988. Clin Pharmacokinet. 1988; 15:367-89.
7. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001; 23:1296-310.
8. Cramer JA, Mattson RH, Prevey ML et al. How often is medication taken as prescribed? A novel assessment technique. JAMA. 1989; 261:3273-7.
9. Depakote ER (divalproex sodium) package insert. North Chicago, IL: Abbott Laboratories; 2003 Jan.
10. Thibault M, Blume WT, Saint-Hilaire JM et al. Divalproex extended-release versus the original divalproex tablet: results of a randomized, crossover study of well-controlled epileptic patients with primary generalized seizures. Epilepsy Res. 2002; 50:243-9.
11. Dutta S, Zhang Y, Selness DS et al. Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers. Epilepsy Res. 2002; 49:1-10.
12. Sommerville KW, Dutta S, Biton V et al. Bioavailability of a divalproex extended-release formulation versus the conventional divalproex formulation in adult patients receiving enzyme-inducing antiepileptic drugs. Clin Drug Invest. 2003; 23:661-70.
13. Freitag F, Collins SD, Carlson HA et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology. 2002; 58:1652-9.
14. Dutta S, Reed RC, Cavanaugh JH. Absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers. J Clin Pharmacol. 2004; 44:737-42.
15. D'Argenio DZ, Schumitzky A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed. 1979; 9:115-34.
16. Dutta S, Cloyd JC, Granneman GR et al. Oral/intravenous maintenance dosing of valproate following intravenous loading: a simulation. Epilepsy Res. 2003; 53:29-38.
17. Cloyd JC, Dutta S, Cao G et al. Valproate unbound fraction and distribution volume following rapid infusions in patients with epilepsy. Epilepsy Res. 2003; 53:19-27.
18. Beydoun A, Sackellares JC, Shu V. Safety and efficacy of divalproex sodium monotherapy in partial epilepsy: a double-blind, concentration-response design clinical trial. Neurology. 1997; 48:182-8.
19. Perucca E, Dulac O, Shorvon S et al. Harnessing the clinical potential of antiepileptic drug therapy - dosage optimization. CNS Drugs. 2001; 15:609-21.
20. Dutta S, Reed RC, Chun AH et al. Morning versus evening dosing of divalproex extended-release tablets does not make a difference: a biopharmaceutic and safety comparison. Epilepsia. 2003; 44(suppl 9):96. Abstract.
21. Yukawa E, To H, Ohdo S et al. Population-based investigation of valproic acid relative clearance using nonlinear mixed effects modeling: influence of drug-drug interaction and patient characteristics. J Clin Pharmacol. 1997; 37:1160-7.
22. Data on file. Abbott Laboratories, Abbott Park, IL; 2004 May.
23. Cloyd JC, Fischer JH, Kriel RL et al. Valproic acid pharmacokinetics in children. IV. Effects of age and antiepileptic drugs on protein binding and intrinsic clearance. Clin Pharmacol Ther. 1993; 53:22-9.
24. Bourdet SV, Gidal BE, Alldredge BK. Pharmacologic management of epilepsy in the elderly. J Am Pharm Assoc. 2001; 41:421-36.